Immix Biopharma, Inc. IMMX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s additional paid-in capital?
- Immix Biopharma, Inc. (IMMX) reported additional paid-in capital of $198.9M in Q1 2026.
- How has Immix Biopharma, Inc.'s additional paid-in capital changed year-over-year?
- Immix Biopharma, Inc.'s additional paid-in capital increased by 122.9% year-over-year, from $89.24M to $198.9M.
- What is the long-term trend for Immix Biopharma, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s additional paid-in capital has grown at a 229.7% compound annual growth rate (CAGR), from $508.87K to $198.29M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.